Pharming Group N.V. revenue

Pharming Group N.V.'s revenue was $376m in fiscal 2025, up 26.6% on the year before. Since fiscal 2019 ($189m) it has grown at a compound 12.1% a year.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Pharming Group N.V.: revenue history, annual
Fiscal year	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	189	212	199	206	245	297	376
Growth on the year before	—	+12.0%	−6.3%	+3.4%	+19.3%	+21.1%	+26.6%
Gross profit	165	189	178	188	220	262	331
Gross margin	87.4%	88.9%	89.4%	91.5%	89.7%	88.1%	87.9%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

Company	Revenue	Growth	3-year growth a year
Pharming Group N.V.	$376m	26.6%	—
Sinovac Biotech LTD	$386m	6.8%	66.1%
Mannkind Corp	$394m	30.5%	35.5%
Meiragtx Holdings plc	$398m	948.3%	296.0%
Novavax Inc	$414m	-61.6%	-36.3%
Iovance Biotherapeutics, Inc.	$325m	34.5%	—

Compare with peers

Head to head: PHAR vs SVA MNKD vs PHAR MGTX vs PHAR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Pharming Group N.V.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Pharming Group N.V.